Retigabine for partial onset seizures

References

• Forsgren L, Hesdorffer D. Epidemiology and prognosis of epilepsy. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 21–31 (2009).
   Google Scholar
• Hauser WA, Annegers JF, Kurland LT. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935–1984. Epilepsia34(3), 453–468 (1993).
   PubMed Web of Science ®Google Scholar
• Perucca E, Tomson T. The pharmacological treatment of epilepsy in adults. Lancet Neurol.10(5), 446–456 (2011).
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet369(9566), 1000–1015 (2007).
   PubMed Web of Science ®Google Scholar
• Brodie M, Barry SJ, Bamagous G, Norrie J, Kwan P. Patterns of treatment response in newly diagnosed epilepsy. Epilepsia52(Suppl. 6), 10 (2011).
   Google Scholar
• Kwan P, Brodie MJ. Early identification of refractory epilepsy. N. Engl. J. Med.342(5), 314–319 (2000).
   PubMed Web of Science ®Google Scholar
• Hermann B, Seidenberg M, Jones J. The neurobehavioural comorbidities of epilepsy: can a natural history be developed? Lancet Neurol.7(2), 151–160 (2008).
   PubMed Web of Science ®Google Scholar
• Christensen J, Vestergaard M, Mortensen PB, Sidenius P, Agerbo E. Epilepsy and risk of suicide: a population-based case–control study. Lancet Neurol.6(8), 693–698 (2007).
   PubMed Web of Science ®Google Scholar
• Tomson T, Nashef L, Ryvlin P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol.7(11), 1021–1031 (2008).
   PubMed Web of Science ®Google Scholar
• White HS, Smith MD, Wilcox KS. Mechanisms of action of antiepileptic drugs. Int. Rev. Neurobiol.81, 85–110 (2007).
   PubMed Web of Science ®Google Scholar
• Pitkanen A, Lukasiuk K. Mechanisms of epileptogenesis and potential treatment targets. Lancet Neurol.10(2), 173–186 (2011).
   PubMed Web of Science ®Google Scholar
• Mansbach H, Baulac M. Retigabine. In: The Treatment of Epilepsy. Shorvon S, Perucca E, Engel J (Eds). Wiley-Blackwell, NJ, USA, 637–646 (2009).
   Google Scholar
• Main MJ, Cryan JE, Dupere JR, Cox B, Clare JJ, Burbidge SA. Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine. Mol. Pharmacol.58(2), 253–262 (2000).
   PubMed Web of Science ®Google Scholar
• Wickenden AD, Yu W, Zou A, Jegla T, Wagoner PK. Retigabine, a novel anticonvulsant, enhances activation of KCNQ2/Q3 potassium channels. Mol. Pharmacol.58(3), 591–600 (2000).
   PubMed Web of Science ®Google Scholar
• Marrion NV. Control of M-current. Annu. Rev. Physiol.59, 483–504 (1997).
   PubMed Web of Science ®Google Scholar
• Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nat. Rev. Drug Discov.8(12), 982–1001 (2009).
   PubMed Web of Science ®Google Scholar
• Singh NA, Charlier C, Stauffer D et al. A novel potassium channel gene, KCNQ2, is mutated in an inherited epilepsy of newborns. Nat. Genet.18(1), 25–29 (1998).
   PubMed Web of Science ®Google Scholar
• Wang HS, Pan Z, Shi W et al. KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel. Science282(5395), 1890–1893 (1998).
   PubMed Web of Science ®Google Scholar
• Wuttke TV, Seebohm G, Bail S, Maljevic S, Lerche H. The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate. Mol. Pharmacol.67(4), 1009–1017 (2005).
   PubMed Web of Science ®Google Scholar
• Rostock A, Tober C, Rundfeldt C et al. D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures. Epilepsy Res.23(3), 211–223 (1996).
   PubMed Web of Science ®Google Scholar
• Tober C, Rostock A, Rundfeldt C, Bartsch R. D-23129: a potent anticonvulsant in the amygdala kindling model of complex partial seizures. Eur. J. Pharmacol.303(3), 163–169 (1996).
   PubMed Web of Science ®Google Scholar
• Mazarati A, Wu J, Shin D, Kwon YS, Sankar R. Antiepileptogenic and anti-ictogenic effects of retigabine under conditions of rapid kindling: an ontogenic study. Epilepsia49(10), 1777–1786 (2008).
   PubMed Web of Science ®Google Scholar
• Bialer M, Johannessen SI, Levy RH, Perucca E, Tomson T, White HS. Progress report on new antiepileptic drugs: a summary of the ninth Eilat Conference (EILAT IX). Epilepsy Res.83(1), 1–43 (2009).
   PubMed Web of Science ®Google Scholar
• Ferron GM, Paul J, Fruncillo R et al. Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers. J. Clin. Pharmacol.42(2), 175–182 (2002).
   PubMed Web of Science ®Google Scholar
• Ferron GM, Patat A, Parks V, Rolan P, Troy SM. Lack of pharmacokinetic interaction between retigabine and phenobarbitone at steady-state in healthy subjects. Br. J. Clin. Pharmacol.56(1), 39–45 (2003).
   PubMed Web of Science ®Google Scholar
• Hermann R, Knebel NG, Niebch G, Richards L, Borlak J, Locher M. Pharmacokinetic interaction between retigabine and lamotrigine in healthy subjects. Eur. J. Clin. Pharmacol.58(12), 795–802 (2003).
   PubMed Web of Science ®Google Scholar
• Hermann R, Ferron GM, Erb K et al. Effects of age and sex on the disposition of retigabine. Clin. Pharmacol. Ther.73(1), 61–70 (2003).
   PubMedGoogle Scholar
• Porter RJ, Partiot A, Sachdeo R, Nohria V, Alves WM. Randomized, multicenter, dose-ranging trial of retigabine for partial-onset seizures. Neurology68(15), 1197–1204 (2007).
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Lerche H, Gil-Nagel A et al. Efficacy and safety of adjunctive ezogabine (retigabine) in refractory partial epilepsy. Neurology75(20), 1817–1824 (2010).
   PubMed Web of Science ®Google Scholar
• French JA, Abou-Khalil BW, Leroy RF et al. Randomized, double-blind, placebo-controlled trial of ezogabine (retigabine) in partial epilepsy. Neurology76(18), 1555–1563 (2011).
   PubMed Web of Science ®Google Scholar
• Rheims S, Perucca E, Cucherat M, Ryvlin P. Factors determining response to antiepileptic drugs in randomized controlled trials. A systematic review and meta-analysis. Epilepsia52(2), 219–233 (2011).
   PubMed Web of Science ®Google Scholar
• Gazzola DM, Balcer LJ, French JA. Seizure-free outcome in randomized add-on trials of the new antiepileptic drugs. Epilepsia48(7), 1303–1307 (2007).
   PubMed Web of Science ®Google Scholar
• Burdette DE, Porter RJ, Lee WJK, Hall S, DeRossett SE. Long-term maintenance of efficacy with ezogabine (retigabine) 600–1200 mg/day: an assessment of three open-label extension studies over 12 months. Neurology76(9), A376–A377 (2011).
   Google Scholar
• Abou-Khalil B, Brodie M, Shaikh S, Lee WJK, Hall S, VanLandingham KE. Seizure-free rates in patients receiving long-term open-label ezogabine (retigabine) 600–1200 mg/day. Neurology76(9), A289–A289 (2011).
   Google Scholar
• Callaghan BC, Anand K, Hesdorffer D, Hauser WA, French JA. Likelihood of seizure remission in an adult population with refractory epilepsy. Ann. Neurol.62(4), 382–389 (2007).
   PubMed Web of Science ®Google Scholar
• Tatulian L, Delmas P, Abogadie FC, Brown DA. Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anticonvulsant drug retigabine. J. Neurosci.21(15), 5535–5545 (2001).
   PubMed Web of Science ®Google Scholar
• Brickel N, Hammond J, Viejo A, VanLandingham KE, Derossett SE. Cardiac safety and rates of sudden unexplained death in patients with partial-onset epilepsy treated with ezogabine (retigabine). Neurology76(9), A616–A616 (2011).
   Google Scholar
• Beyenburg S, Stavem K, Schmidt D. Placebo-corrected efficacy of modern antiepileptic drugs for refractory epilepsy: systematic review and meta-analysis. Epilepsia51(1), 7–26 (2010).
   PubMed Web of Science ®Google Scholar
• Ryvlin P, Cucherat M, Rheims S. Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. Lancet Neurol.10(11), 961–968 (2011).
   PubMed Web of Science ®Google Scholar
• Ravizza T, Lucas SM, Balosso S et al. Inactivation of caspase-1 in rodent brain: a novel anticonvulsive strategy. Epilepsia47(7), 1160–1168 (2006).
   PubMed Web of Science ®Google Scholar
• Wong M. Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: from tuberous sclerosis to common acquired epilepsies. Epilepsia51(1), 27–36 (2010).
   PubMed Web of Science ®Google Scholar